Jones Financial Companies
LCTX icon

Jones Financial Companies’s Lineage Cell Therapeutics LCTX Stock Holding History

Jones Financial Companies’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.3K Sell
1,800
-2,700
-60% -$3.73K ﹤0.01% 4392
2026
Q1 		$6.71K Buy
4,500
+2,500
+125% +$4.22K ﹤0.01% 3727
2025
Q4 		$3.34K Buy
2,000
+1,100
+122% +$1.9K ﹤0.01% 3662
2025
Q3 		$1.54K Buy
900
+200
+29% +$237 ﹤0.01% 3775
2025
Q2 		$655 Hold
700
– – ﹤0.01% 3751
2025
Q1 		$344 Hold
700
– – ﹤0.01% 3554
2024
Q4 		$351 Buy
+700
New +$514 ﹤0.01% 3268

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Jones Financial Companies's LCTX Position: Q2 2026 in Review

Jones Financial Companies reduced its Lineage Cell Therapeutics (LCTX) stake by 60% in Q2 2026, selling an estimated $3.73K and leaving 1,800 shares worth $2.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4392.

Jones Financial Companies first reported a position in LCTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $6.71K in Q1 2026. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Jones Financial Companies held 1,800 shares of Lineage Cell Therapeutics worth $2.3K as of Q2 2026.
  • Jones Financial Companies sold 2,700 Lineage Cell Therapeutics shares in Q2 2026, an estimated $3.73K.
  • Lineage Cell Therapeutics made up ﹤0.01% of Jones Financial Companies's portfolio in Q2 2026, its #4392 holding.
  • Jones Financial Companies first reported a position in Lineage Cell Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Jones Financial Companies's Lineage Cell Therapeutics position peaked at $6.71K in Q1 2026.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Jones Financial Companies's 13F filing for Q2 2026, filed 14 Aug 2026.